Clinica Universidad de Navarra

Pamplona, Navarre 31080

25 studies enrolling now · 88 studies all time

What they study most

ALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC, Acute Myeloid Leukemia, Adult B Cell ALL, Advanced Melanoma, Advanced Prostate Cancer, Advanced Solid Tumors, Advanced and/or Metastatic Solid Tumours, Aggressive B-cell Non-Hodgkin Lymphoma (aNHL), Alzheimer's Disease, Alzheimer's Disease Dementia, Atopic Dermatitis, Atrial Fibrillation (AF)

Studies at this site

• A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer — Recruiting now
• Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer — Recruiting now
• A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis — Recruiting now
• Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants With Advanced Solid Tumors — Recruiting now
• Pan Tumor Rollover Study — Recruiting now
• A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors — Recruiting now
• A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer — Recruiting now
• A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2) — Recruiting now
• Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers — Recruiting now
• Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis — Recruiting now
• A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant — Recruiting now
• A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments — Recruiting now
• A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC) — Recruiting now
• Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM) — Recruiting now
• Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC — Recruiting now
• A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease — Recruiting now
• A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas — Recruiting now
• A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment — Recruiting now
• A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments — Recruiting now
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s) — Recruiting now
• Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma — Recruiting now
• A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma — Recruiting now
• A Phase 1b/2 Study of IM-101 in Adult Participants With Generalized Myasthenia Gravis and Ocular Myasthenia Gravis — Recruiting now
• A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors — Recruiting now
• First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma — Running, not enrolling
• Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06) — Running, not enrolling
• TheraSphere With Durvalumab and Tremelimumab for HCC — Running, not enrolling
• A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis — Enrolling by invitation
• A Global Study Comparing Pulsed Field Ablation With Electrographic Flow Mapping Versus Posterior Wall Ablation for Persistent Atrial Fibrillation — Running, not enrolling
• A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2 — Running, not enrolling
• A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) — Stopped early
• Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine — Running, not enrolling
• A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma — Running, not enrolling
• A Study to Learn About the Safety of Diranersen (BIIB080) Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age — Running, not enrolling
• A Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon) — Completed
• A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease — Running, not enrolling
• A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80 — Completed
• A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL — Running, not enrolling
• Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute) — Running, not enrolling
• Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) — Running, not enrolling
• AMX0035 and Progressive Supranuclear Palsy — Completed
• Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC) — Running, not enrolling
• A Study of TAK-503 in Children and Teenagers With Attention Deficit Hyperactivity Disorder (ADHD) — Completed
• Erenumab - Comprehensive Assessment of Efficacy in (High-Frequency) Episodic Migraine — Completed
• ExAblate Pallidotomy for Medically-Refractory Dyskinesia Symptoms or Motor Fluctuations of Advanced Parkinson's Disease — Running, not enrolling
• A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer — Running, not enrolling
• Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma — Completed
• TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A) — Running, not enrolling
• A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran (RO7198457) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Participants With Previously Untreated Advanced Melanoma. — Completed
• A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH — Stopped early